Patents Assigned to Pfizer
  • Isothiazole derivatives
    Publication number: 20040147574
    Abstract: Novel isothiazole compounds, including derivatives thereof, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, hyperproliferative disorders and fibrotic diseases.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventor: Michael J. Munchhof
  • Attenuated forms of bovine viral diarrhea virus
    Publication number: 20040146854
    Abstract: The present invention relates to attenuated forms of bovine viral diarrhea (BVD) viruses. In particular, the present invention relates to attenuated BVD viruses made by mutating the Npro protease gene and inserting a bovine ubiquitin coding sequence. The attenuated viruses of the present invention can be used to raise antibodies against BVDV. Immunogenic compositions and vaccine compositions, as well as therapeutic and diagnosis methods, are also provided by the present invention.
    Type: Application
    Filed: November 21, 2001
    Publication date: July 29, 2004
    Applicant: Pfizer Inc.
    Inventors: Xuemei Cao, Gabriele M. Zybarth
  • Depot formulations in the form of a suspension
    Publication number: 20040146562
    Abstract: A pharmaceutical kit for preparing an injectable depot formulation of an aryl-heterocyclic pharmaceutical compound, such as ziprasidone, and a method of preparing said depot formulation is disclosed.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventor: Jaymin C. Shah
  • Inhibiting oxidative degradation of pharmaceutical formulations
    Patent number: 6767558
    Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceutical excipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceutical excipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: July 27, 2004
    Assignee: Pfizer Inc.
    Inventor: Hai Wang
  • Solid and semi-solid polymeric ionic conjugates
    Publication number: 20040142039
    Abstract: Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 22, 2004
    Applicant: Pfizer Inc
    Inventors: Shalaby W. Shalaby, Jaymin C. Shah, Joel T. Corbett
  • Novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
    Publication number: 20040143119
    Abstract: The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment. 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is a potent inhibitor of MAP kinases, preferably p38 kinase (MAPK14/CSBP/RK kinase). 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Application
    Filed: August 27, 2003
    Publication date: July 22, 2004
    Applicant: Pfizer Inc
    Inventors: Ming Kang, Zheng Jane Li, Zhengong Bryan Li, Yong Tao
  • 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
    Publication number: 20040142924
    Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula 1
    Type: Application
    Filed: October 3, 2003
    Publication date: July 22, 2004
    Applicant: Pfizer Inc
    Inventor: Jon A. Low
  • Pyridylfuran and pyridylthiophene compounds
    Publication number: 20040142976
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: January 6, 2004
    Publication date: July 22, 2004
    Applicant: Pfizer Inc.
    Inventors: Akiyoshi Kawai, Makoto Kawai
  • Therapeutic use of alpha-2-delta ligands
    Publication number: 20040143014
    Abstract: The instant invention relates to the use of an alpha-2-delta ligand in the treatment of chronic obstructive pulmonary disease (COPD) and diseases associated with a diagnosis of COPD, and particularly to the treatment of chronic cough, which may be unrelated to COPD.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 22, 2004
    Applicant: Pfizer Inc
    Inventors: Claude Philippe Bertrand, Maria Emilia Pereira Chicau Chovet, Pierangelo Geppetti, Charles Price Taylor, Andrew John Thorpe, David Juergen Wustrow
  • Pyrrolopyrimidines as CRF antagonists
    Patent number: 6765008
    Abstract: The compounds of the formula wherein R1, R2, R3, R4, R5 and R6 are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.
    Type: Grant
    Filed: June 14, 1995
    Date of Patent: July 20, 2004
    Assignee: Pfizer Inc
    Inventor: Yuhpyng Liang Chen
  • Use of o-vanillin and o-vanillin/trolox combinations
    Patent number: 6764993
    Abstract: The invention provides methods of protecting solid-state proteins from the effects of ionizing radiation which comprise combining the protein with a radiation-protecting amount of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol, prior to exposing the protein to ionizing radiation.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: July 20, 2004
    Assignee: Pfizer Inc.
    Inventors: Evgenyi Y. Shalaev, Renuka D. Reddy, Roger N. Kimball
  • Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
    Patent number: 6764676
    Abstract: The present invention is directed to a novel strain of feline immunodeficiency virus, designated herein as FIV-141, and to attenuated forms of the virus produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: July 20, 2004
    Assignee: Pfizer Inc.
    Inventors: Ruitang Deng, Michael G. Sheppard
  • Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
    Patent number: 6763607
    Abstract: Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: July 20, 2004
    Assignee: Pfizer Inc.
    Inventors: Ronald A. Beyerinck, Heather L. M. Deibele, Dan E. Dobry, Roderick J. Ray, Dana M. Settell, Ken R. Spence
  • Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
    Patent number: 6765023
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted reverse aminoalcohols.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: July 20, 2004
    Assignee: Pfizer, Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Modulators of the glucocorticoid receptor
    Publication number: 20040138262
    Abstract: The present invention provides compounds of the formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: July 15, 2004
    Applicant: Pfizer Inc.
    Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson
  • Enzyme PDE XVI
    Publication number: 20040137508
    Abstract: Amino acid sequences and nucleotide sequences relating to PDE_XIV are described. In a preferred aspect, the amino acid sequences comprise the sequence presented as SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5.
    Type: Application
    Filed: February 18, 2004
    Publication date: July 15, 2004
    Applicant: Pfizer Inc.
    Inventor: Mark D. Fidock
  • Histamine receptor antagonists
    Publication number: 20040138234
    Abstract: The present invention provides a combination of (a) a histamine H1 receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H4 receptor as compared to the histamine H3 receptor; and an antagonist that is at least 10-fold selective for the histamine H4 receptor as compared to the histamine H3 receptor: and compositions and uses thereof.
    Type: Application
    Filed: December 16, 2003
    Publication date: July 15, 2004
    Applicant: Pfizer Inc
    Inventors: Stephen Jenkinson, Mark Anthony O'Reilly, Michael Andrew Trevethick
  • 4,4-Biarylpiperidine derivatives
    Publication number: 20040138220
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: December 23, 2003
    Publication date: July 15, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventor: Spiros Liras
  • Novel injectable depot formulations
    Publication number: 20040138237
    Abstract: An injectable depot formulation that is viscous, or becomes viscous in situ, comprising a solubilized aryl-heterocyclic pharmaceutical compound, such as ziprasidone, is provided.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 15, 2004
    Applicant: Pfizer Inc
    Inventor: Jaymin C. Shah
  • Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity
    Publication number: 20040138232
    Abstract: A process for preparing acyl derivatives as prodrugs of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2H-indol-2-one and pharmaceutically acceptable acid addition salts and methods of use as an antipsychotic.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 15, 2004
    Applicant: Pfizer Inc
    Inventors: Roberto Colon-Cruz, Timothy Norris